Skip to main content

Table 2 Incidences of LRR, DM and death from all causes among different subtypes

From: Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy

Events

Incidences

Subtypes

P**

TNBC is defined as ER/PR positive staining in <1% cells

 

Alla (n = 157)

HR+/HER2− (ER/PR ≥1%) (n = 75)

HER2+ (n = 46)

TN (ER/PR <1%) (n = 36)

P

 LRR

12b

(7.6%)

4

(5.3%) (p = 0.037)π

1

(2.2%) (p = 0.019)π

7

(19.4%)

0.014

 DM

22

(14.0%)

11

(14.7%) (p = 0.78)π

5

(10.9%) (p = 0.52)π

6

(16.7%)

0.73

 Death

21

(13.4%)

8

(10.7%) (p = 1.0)π

7

(15.2%) (p = 0.75)π

4

(11.1%)

0.77

 

Non-pCR (n = 132)

HR+/HER2− (ER/PR ≥1%) (n = 71)

HER2+ (n = 34)

TN (ER/PR <1%) (n = 27)

P

 LRR

11

(8.3%)

4

(5.6%) (p = 0.025)π

1

(3.0%) (p = 0.037)π

6

(22.2%)

0.023

 DM

21

(15.9%)

11

(15.5%) (p = 0.76)π

5

(14.7%) (p = 0.74)π

5

(18.5%)

0.90

 Death

19

(14.4%)

8

(11.3%) (p = 0.73)π

7

(20.6%) (p = 0.74)π

4

(14.8%)

0.40

TNBC is defined as ER/PR positive staining in <10% cells

 

Alla (n = 157)

HR+/HER2− (ER/PR ≥10%) (n = 68)

HER2+ (n = 46)

TN (ER/PR <10%) (n = 43)

P

 LRR

12b

(7.6%)

2

(2.9%) (p = 0.003)π

1

(2.2%) (p = 0.006)π

9

(20.9%)

0.001

 DM

22

(14.0%)

9

(13.2%) (p = 0.59)π

5

(10.9%) (p = 0.37)π

8

(18.6%)

0.59

 Death

21

(13.4%)

5

(7.3%) (p = 0.21)π

7

(15.2%) (p = 1.0)π

7

(16.3%)

0.27

 

Non-pCR (n = 132)

HR+/HER2− (ER/PR ≥10%) (n = 64)

HER2+ (n = 34)

TN (ER/PR< 10%) (n = 34)

P

 LRR

11

(8.3%)

2

(3.3%) (p = 0.003)π

1

(2.9%) (p = 0.027)π

8

(23.5%)

0.002

 DM

21

(15.9%)

9

(14.8%) (p = 0.41)π

5

(14.7%) (p = 0.75)π

7

(20.6%)

0.68

 Death

19

(14.4%)

5

(7.8%) (p = 0.10)π

7

(20.6%) (p = 1.0)π

7

(20.6%)

0.11

  1. Triple negative breast cancer was defined as ER and PR positive staining either in <1% cells or in <10% cells as shown respectively.
  2. All LRR and DM are counted as first site of failure.
  3. ** P values are obtained using Fisher’s exact tests with two degree-of-freedom.
  4. P values are calculated using Fisher’s exact tests comparing with TN subtype.
  5. aThere were three patients who had no HER2 status documented.
  6. bTwo of the LRR occurred simultaneously with DM.